Nautigen
Nautigen is a U.S. biotech startup developing noninvasive remote sensing and biomolecular technologies to discover and catalog novel bioactive molecules from deep-sea ecosystems, primarily licensing biomolecular data to pharmaceutical companies and academic institutions for drug discovery research.
- Company typePrivate
- Founded2024
- HeadquartersWilmington, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Nautigen does
Nautigen Marine Biomolecular Exploration, Inc. is a U.S.-based biotechnology startup founded in 2024 and headquartered in Wilmington, Delaware. The company is developing noninvasive remote sensing and biomolecular technologies to discover novel bioactive molecules in deep-sea ecosystems for pharmaceutical and research applications. Its platform pairs deep-sea sample access (planned via partnerships with mineral exploration operators) with metadata-rich cataloging intended to produce a digital biomolecular dataset structured for drug discovery workflows.
The intended product is a digital catalog of biomolecular data with categorization suitable for AI-driven pharmaceutical pipelines. Nautigen targets two primary segments: pharmaceutical companies seeking novel bioactive compounds for drug development, and academic institutions conducting marine biology and pharmaceutical sciences research. The company plans to monetize primarily through licensing of biomolecular data to these B2B customers, using quote-based, negotiated engagements rather than disclosed standard pricing.
The company is at an early stage with 1-10 employees, no disclosed funding, no disclosed customers, and no commercial revenue. It plans to begin operations within the U.S. Exclusive Economic Zone to avoid international regulatory delays, with the founder (a former Fugro marine geodata specialist) serving as the sole named operator and the driving force behind technology, partnership, and commercialization decisions.
Nautigen firmographics
Firmographics- Name
- Nautigen
- Legal name
- Nautigen Marine Biomolecular Exploration, Inc.
- Website
- https://nautigen.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nautigen is a U.S. biotech startup developing noninvasive remote sensing and biomolecular technologies to discover and catalog novel bioactive molecules from deep-sea ecosystems, primarily licensing biomolecular data to pharmaceutical companies and academic institutions for drug discovery research.
- Ownership category
- akta.pro rank
Nautigen industry classification
Industry- Product category
- Marine Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
Keywords
Where Nautigen is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Markets served
Nautigen business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Biomolecular Data Licensing: The company aims to monetize its digital catalog of biomolecular data by licensing access to pharmaceutical companies and academic institutions. Revenue would come from providing categorized metadata-enriched biomolecular data for drug discovery and research applications, potentially through subscription or per-query licensing arrangements.
Go-to-market motion1 record
Nautigen product offering
Product offeringCore offering
Nautigen develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company builds a digital catalog of structured biomolecular data, enriched with metadata, and plans to license access to pharmaceutical companies and academic institutions for drug discovery and research applications. Sample collection is intended to occur through partnerships with deep-sea mineral exploration firms, with initial operations within the U.S. exclusive economic zone.
Product overview
Nautigen offers a marine biomolecular exploration platform that develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company operates as a single unified product focused on pharmaceutical and other applications, building a digital catalog of biomolecular data categorized with metadata for pharmaceutical companies and academic institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Nautigen Marine Biomolecular Exploration Platform A biotechnology platform that uses noninvasive remote sensing and biomolecular technologies to discover, identify, and catalog novel bioactive marine molecules from deep-sea ecosystems. The platform produces a structured digital catalog of biomolecular data enriched with metadata, intended to be licensed to pharmaceutical companies and academic institutions for drug discovery, marine biology research, and AI-driven pharmaceutical development.
- Deep-Sea Biomolecular Data Catalog A structured, metadata-enriched digital catalog of bioactive marine molecules derived from deep-sea ecosystems, intended to be licensed to pharmaceutical companies and academic institutions. The catalog is designed to support drug discovery pipelines, marine biology research, pharmaceutical sciences, and AI-driven drug discovery workflows through query or subscription access.
Quantifiable outcome
- Deep-sea exploration could advance AI-driven drug discovery and lead to more affordable pharmaceuticals
Companies that use Nautigen
Customer profileSegments2 records
Ideal customer profiles2 records
Nautigen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Nautigen partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Nautigen competitors and assessment
Company assessmentBroad incumbents
- Recursion Pharmaceuticals: AI-native drug discovery company that combines high-throughput biology with proprietary data assets. Relevant because it is a mature example of the data-as-asset, AI-driven drug discovery model Nautigen aspires to.
- Ginkgo Bioworks: Large biotech platform company that operates a biological data and engineering infrastructure for customer R&D. Comparable as a data/platform-as-a-service biology company serving pharmaceutical customers.
- Benchling: Cloud-based R&D platform for life sciences that manages scientific data and workflows for biotech and pharma customers. Adjacent comparable as a B2B data platform serving the same customer base.
- Schrödinger: Computational chemistry and AI-driven drug discovery platform that licenses software and molecular data to pharmaceutical companies. Comparable as an established incumbent in the AI/biomolecular data licensing category Nautigen is targeting.
Direct peers
- Marinomed Biotech: Austrian biotech that develops therapeutics based on marine and natural product compounds. Comparable in that it is a smaller, science-driven company commercializing marine bioactives into the pharmaceutical market.
- Aker BioMarine: Norwegian company that harvests marine organisms (krill) from deep, cold waters for nutraceutical, pharmaceutical, and aquaculture applications. Highly relevant because it demonstrates the deep-sea-to-pharma commercial model Nautigen is attempting to enter.
- PharmaMar: Spanish pharmaceutical company that develops marine-derived anticancer drugs (e.g., trabectedin, plitidepsin). Direct competitor because it commercializes bioactive molecules isolated from marine organisms for the same pharmaceutical customers Nautigen targets.
Emerging players
- Insitro: AI-driven drug discovery company building proprietary datasets to fuel machine learning models for pharmaceutical applications. Comparable in that it is constructing novel biological datasets as a core asset for pharma licensing.
- Dotmatics: Scientific informatics and data management platform for life sciences R&D. Comparable as a software/data platform that aggregates and structures biological data for pharma researchers.
- Kalyagen: Biotech focused on natural product-derived biologics and stem cell therapies. Comparable as a smaller, emerging natural-product biotech exploring novel source organisms for therapeutic development.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Nautigen social profiles
Digital presenceNautigen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nautigen leadership team
Management profileNumber of profiles
Profiles1 record
Nautigen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nautigen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nautigen
What does Nautigen do?
Nautigen develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company builds a digital catalog of structured biomolecular data, enriched with metadata, and plans to license access to pharmaceutical companies and academic institutions for drug discovery and research applications. Sample collection is intended to occur through partnerships with deep-sea mineral exploration firms, with initial operations within the U.S. exclusive economic zone.
Is Nautigen a public or private company?
Nautigen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nautigen founded?
Nautigen was founded in 2024. It employs 1 to 10 people.
Where is Nautigen based?
Nautigen is headquartered in Wilmington, United States, in the North America region.
How does Nautigen make money?
One revenue line is on record: biomolecular Data Licensing.
Who are Nautigen's main competitors?
Broad incumbents on record are Recursion Pharmaceuticals, Ginkgo Bioworks, Benchling and Schrödinger. Direct peers are Marinomed Biotech, Aker BioMarine and PharmaMar. Emerging players are Insitro, Dotmatics and Kalyagen.
Does Nautigen have an API?
No public API is recorded for Nautigen.
What industry is Nautigen in?
Nautigen's product category is Marine Biotechnology. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 2833.